Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

por Toledo-Romani, María Eugenia, García-Carmenate, Mayra, Verdecia-Sánchez, Leslyhana, Pérez-Rodríguez, Suzel, Rodriguez-González, Meybis, Valenzuela-Silva, Carmen, Paredes-Moreno, Beatriz, Sanchez-Ramirez, Belinda, González-Mugica, Raúl, Hernández-Garcia, Tays, Orosa-Vázquez, Ivette, Díaz-Hernández, Marianniz, Pérez-Guevara, María Teresa, Enriquez-Puertas, Juliet, Noa-Romero, Enrique, Palenzuela-Diaz, Ariel, Baro-Roman, Gerardo, Mendoza-Hernández, Ivis, Muñoz, Yaima, Gómez-Maceo, Yanet, Santos-Vega, Bertha Leysi, Fernandez-Castillo, Sonsire, Climent-Ruiz, Yanet, Rodríguez-Noda, Laura, Santana-Mederos, Darielys, García-Vega, Yanelda, Chen, Guang-Wu, Doroud, Delaram, Biglari, Alireza, Boggiano-Ayo, Tammy, Valdés-Balbín, Yury, Rivera, Daniel G., García-Rivera, Dagmar, Vérez-Bencomo, Vicente
Publicado 2022